0001413329false00014133292024-09-172024-09-170001413329us-gaap:CommonStockMember2024-09-172024-09-170001413329pm:A0.625Notesdue2024Member2024-09-172024-09-170001413329pm:A3.250Notesdue2024Member2024-09-172024-09-170001413329pm:A2.750Notesdue2025Member2024-09-172024-09-170001413329pm:A3.375Notesdue2025Member2024-09-172024-09-170001413329pm:A2.750Notesdue2026Member2024-09-172024-09-170001413329pm:A2.875Notesdue2026Member2024-09-172024-09-170001413329pm:A0.125Notesdue2026Member2024-09-172024-09-170001413329pm:A3.125Notesdue2027Member2024-09-172024-09-170001413329pm:A3.125Notesdue2028Member2024-09-172024-09-170001413329pm:A2.875Notesdue2029Member2024-09-172024-09-170001413329pm:A3.375Notesdue2029Member2024-09-172024-09-170001413329pm:A3.750NotesDue2031Member2024-09-172024-09-170001413329pm:A0.800Notesdue2031Member2024-09-172024-09-170001413329pm:A3.125Notesdue2033Member2024-09-172024-09-170001413329pm:A2.000Notesdue2036Member2024-09-172024-09-170001413329pm:A1.875Notesdue2037Member2024-09-172024-09-170001413329pm:A6.375Notesdue2038Member2024-09-172024-09-170001413329pm:A1.450Notesdue2039Member2024-09-172024-09-170001413329pm:A4.375Notesdue2041Member2024-09-172024-09-170001413329pm:A4.500Notesdue2042Member2024-09-172024-09-170001413329pm:A3.875Notesdue2042Member2024-09-172024-09-170001413329pm:A4.125Notesdue2043Member2024-09-172024-09-170001413329pm:A4.875Notesdue2043Member2024-09-172024-09-170001413329pm:A4.250Notesdue2044Member2024-09-172024-09-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 8-K



CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 17, 2024



Philip Morris International Inc.
(Exact name of registrant as specified in its charter)

Virginia
1-33708
13-3435103
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)

677 Washington Blvd, Ste. 1100StamfordConnecticut06901
(Address of principal executive offices)(Zip Code)


Registrant's telephone number, including area code: (203) 905-2410
(Former name or former address, if changed since last report.)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, no par valuePMNew York Stock Exchange
0.625% Notes due 2024PM24BNew York Stock Exchange
3.250% Notes due 2024PM24ANew York Stock Exchange
2.750% Notes due 2025PM25New York Stock Exchange
3.375% Notes due 2025PM25ANew York Stock Exchange
2.750% Notes due 2026PM26ANew York Stock Exchange
2.875% Notes due 2026PM26New York Stock Exchange
0.125% Notes due 2026PM26BNew York Stock Exchange
3.125% Notes due 2027PM27New York Stock Exchange
3.125% Notes due 2028PM28New York Stock Exchange
2.875% Notes due 2029PM29New York Stock Exchange
3.375% Notes due 2029PM29ANew York Stock Exchange
3.750% Notes due 2031PM31BNew York Stock Exchange
0.800% Notes due 2031PM31New York Stock Exchange
3.125% Notes due 2033PM33New York Stock Exchange
2.000% Notes due 2036PM36New York Stock Exchange
1.875% Notes due 2037PM37ANew York Stock Exchange
6.375% Notes due 2038PM38New York Stock Exchange
1.450% Notes due 2039PM39New York Stock Exchange
4.375% Notes due 2041PM41New York Stock Exchange
4.500% Notes due 2042PM42New York Stock Exchange
3.875% Notes due 2042PM42ANew York Stock Exchange
4.125% Notes due 2043PM43New York Stock Exchange
4.875% Notes due 2043PM43ANew York Stock Exchange
4.250% Notes due 2044PM44New York Stock Exchange



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


                                                
         Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐



Item 8.01.Other Events.

On September 17, 2024 Philip Morris International Inc. (the “Company”) announced the execution of a definitive agreement pursuant to which the Company’s direct, wholly-owned subsidiary, Vectura Fertin Pharma Inc., agreed to sell Vectura Group Ltd. (“Vectura”), its subsidiary, and Vectura’s subsidiaries to Molex Asia Holdings Ltd. (the “Sale”), for upfront cash consideration of GBP 150 million (approximately $198 million), subject to customary purchase price adjustments, and up to GBP 148 million (approximately $195 million) in deferred payments contingent on achievement of certain milestones over periods up to and through 2039. The transaction is expected to close by the end of 2024, subject to regulatory approval, which may impact the timing, and other customary closing conditions.

In connection with the approval of the Sale by the Company’s Board of Directors on September 12, 2024, the Company expects to record an estimated loss of approximately $220 million associated with the Sale during the third quarter of 2024, subject to working capital and other adjustments.

The Company issued a press release on September 17, 2024, announcing the transaction. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits.



104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document and contained in Exhibit 101)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHILIP MORRIS INTERNATIONAL INC.
By:/s/ DARLENE QUASHIE HENRY
Name:Darlene Quashie Henry
Title:Vice President, Associate General Counsel & Corporate Secretary
Date: September 17, 2024


Exhibit 99.1
image_0.jpg
Contact:
David Fraser
Philip Morris International
T. +41 (0)58 242 4500
E. david.fraser@pmi.com

Vectura Fertin Pharma, Inc., a Subsidiary of Philip Morris International, Announces Agreement for Sale of Vectura Group to Molex

STAMFORD, CT—SEPT. 17, 2024—Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE: PM), today announces the sale of its subsidiary Vectura Group Ltd. (Vectura) to Molex Asia Holdings Ltd., and the establishment of master service agreements to develop Vectura Fertin Pharma’s inhaled therapeutics proprietary pipeline. Vectura will be operated by Phillips Medisize, a Molex company. The sale includes upfront cash consideration of GBP 150 million, subject to customary purchase price adjustments, and potential deferred payments of up to GBP 148 million. The transaction is subject to customary closing conditions, including regulatory approval.

“In line with our ambitions, Vectura has enabled us to develop a proprietary pipeline of inhaled therapeutics, and we remain committed to driving innovation in this space over the long-term,” said Jacek Olczak, PMI Chief Executive Officer.

PMI’s 2021 acquisition of Vectura has been instrumental in kick-starting Vectura Fertin Pharma’s development of inhaled therapeutics, bringing to the company specialist knowledge, technologies, and formulation science. However, despite the investment and commitment to developing products and therapies vital to patients, unwarranted opposition to PMI’s transformation has impacted Vectura’s scientific engagement and commercial CDMO relationships.

Mr. Olczak added: “With its experience in pharmaceutical drug delivery devices and its global manufacturing footprint, Phillips Medisize is best placed to lead Vectura into the future—while releasing it from the unreasonable burden of external constraints and criticism related to our ownership.”

The remaining units of Vectura Fertin Pharma will continue to operate as a separate company under PMI’s ownership and will be given a new corporate identity. This business will focus on developing and commercializing oral consumer health and wellness offerings and inhaled prescription products for therapy areas that include pain management and cardiovascular emergencies.

Phillips Medisize is a global company that designs, engineers, and manufactures drug delivery systems, medical devices, and in vitro diagnostic products. The company’s more than 6,000 employees collaborate with customers at 29 sites throughout North America, Europe, and Asia. Adding the Vectura team and its market-leading capabilities in inhalation aligns with Phillips Medisize’s stated mission of working with customers to develop innovative products that help people live healthier, more productive lives.

Notes To Editor

Definitions:
•CDMO: contract development and manufacturing organization

1

image_0.jpg

Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested over $12.5 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In 2022, PMI acquired Swedish Match—a leader in oral nicotine delivery—creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS devices and consumables and Swedish Match’s General snus as Modified Risk Tobacco Products, and renewal applications for these products are presently pending before the FDA. As of June 30, 2024, PMI’s smoke-free products were available for sale in 90 markets, and PMI estimates that 36.5 million adults around the world use PMI’s smoke-free products. Smoke-free business accounted for approximately 38% of PMI’s total first-half 2024 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. “PMI” refers to Philip Morris International Inc. and its subsidiaries. For more information, please visit www.pmi.com and www.pmiscience.com.
About Phillips Medisize
Phillips Medisize, a Molex company, collaborates with leading pharmaceutical, medical technology and in vitro diagnostic companies to design, engineer and manufacture life-saving innovations. A contract development and manufacturing organization (CDMO), Phillips Medisize leverages its 60 years of expertise and globally renowned capabilities to deliver products and solutions that annually help millions of patients, healthcare professionals and individuals live healthier, more productive lives. For more information, visit www.phillipsmedisize.com.
About Molex
Molex is a global electronics leader committed to making the world a better, more connected place. With a presence in more than 40 countries, Molex enables transformative technology innovation in the automotive, data center, industrial automation, healthcare, 5G, cloud and consumer device industries. Through trusted customer and industry relationships, unrivaled engineering expertise, and product quality and reliability, Molex realizes the infinite potential of Creating Connections for Life. For more information, visit www.molex.com.
Forward-Looking and Cautionary Statements
This press release contains projections of future results and goals and other forward-looking statements, including statements regarding the timing of and ability to complete the Vectura sale transaction; expected benefits of the transaction and of the continuing commercial relationship; the receipt of deferred payments; expected operational performance; and business plans and strategies. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying






2

image_0.jpg

important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI. The factors that may adversely impact the anticipated outcomes include, among others: the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement; the outcome of any legal proceedings that may be instituted against the parties or others related to the transaction agreement; conditions to the completion of the transaction may not be satisfied, or the regulatory approvals required for the transaction may not be obtained on the terms expected or on the anticipated schedule; the parties' ability to meet expectations regarding the timing, completion and other elements of the transaction may be different than currently planned; and the possibility that the expected benefits of the transaction, of the continuing commercial relationship between the parties, or of PMI’s business plans and strategies may not materialize in the expected manner or timeframe, if at all. PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2023, and the Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.
    

3

v3.24.3
Document and Entity Information
Sep. 17, 2024
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Sep. 17, 2024
Entity Registrant Name Philip Morris International Inc.
Entity Central Index Key 0001413329
Amendment Flag false
Entity Incorporation, State or Country Code VA
Entity File Number 1-33708
Entity Tax Identification Number 13-3435103
Entity Address, Address Line One 677 Washington Blvd, Ste. 1100
Entity Address, City or Town Stamford
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06901
City Area Code 203
Local Phone Number 905-2410
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, no par value
Trading Symbol PM
Security Exchange Name NYSE
0.625% Notes due 2024 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 0.625% Notes due 2024
Trading Symbol PM24B
Security Exchange Name NYSE
3.250% Notes due 2024 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 3.250% Notes due 2024
Trading Symbol PM24A
Security Exchange Name NYSE
2.750% Notes due 2025 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 2.750% Notes due 2025
Trading Symbol PM25
Security Exchange Name NYSE
3.375% Notes due 2025 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 3.375% Notes due 2025
Trading Symbol PM25A
Security Exchange Name NYSE
2.750% Notes due 2026 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 2.750% Notes due 2026
Trading Symbol PM26A
Security Exchange Name NYSE
2.875% Notes due 2026 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 2.875% Notes due 2026
Trading Symbol PM26
Security Exchange Name NYSE
0.125% Notes due 2026 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 0.125% Notes due 2026
Trading Symbol PM26B
Security Exchange Name NYSE
3.125% Notes due 2027 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 3.125% Notes due 2027
Trading Symbol PM27
Security Exchange Name NYSE
3.125% Notes due 2028 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 3.125% Notes due 2028
Trading Symbol PM28
Security Exchange Name NYSE
2.875% Notes due 2029 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 2.875% Notes due 2029
Trading Symbol PM29
Security Exchange Name NYSE
3.375% Notes due 2029 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 3.375% Notes due 2029
Trading Symbol PM29A
Security Exchange Name NYSE
0.800% Notes due 2031 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 0.800% Notes due 2031
Trading Symbol PM31
Security Exchange Name NYSE
3.125% Notes due 2033 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 3.125% Notes due 2033
Trading Symbol PM33
Security Exchange Name NYSE
2.000% Notes due 2036 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 2.000% Notes due 2036
Trading Symbol PM36
Security Exchange Name NYSE
1.875% Notes due 2037 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 1.875% Notes due 2037
Trading Symbol PM37A
Security Exchange Name NYSE
6.375% Notes due 2038 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 6.375% Notes due 2038
Trading Symbol PM38
Security Exchange Name NYSE
1.450% Notes due 2039 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 1.450% Notes due 2039
Trading Symbol PM39
Security Exchange Name NYSE
4.375% Notes due 2041 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 4.375% Notes due 2041
Trading Symbol PM41
Security Exchange Name NYSE
4.500% Notes due 2042 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 4.500% Notes due 2042
Trading Symbol PM42
Security Exchange Name NYSE
3.875% Notes due 2042 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 3.875% Notes due 2042
Trading Symbol PM42A
Security Exchange Name NYSE
4.125% Notes due 2043 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 4.125% Notes due 2043
Trading Symbol PM43
Security Exchange Name NYSE
4.875% Notes due 2043 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 4.875% Notes due 2043
Trading Symbol PM43A
Security Exchange Name NYSE
4.250% Notes due 2044 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 4.250% Notes due 2044
Trading Symbol PM44
Security Exchange Name NYSE
3.750% Notes due 2031  
Entity Information [Line Items]  
Title of 12(b) Security 3.750% Notes due 2031
Trading Symbol PM31B
Security Exchange Name NYSE
Philip Morris (NYSE:PM)
過去 株価チャート
から 11 2024 まで 12 2024 Philip Morrisのチャートをもっと見るにはこちらをクリック
Philip Morris (NYSE:PM)
過去 株価チャート
から 12 2023 まで 12 2024 Philip Morrisのチャートをもっと見るにはこちらをクリック